Hematological Disease Biospecimens: Tracking Clonal Evolution Through Serial Sampling

Hematological malignancies and disorders offer unique research opportunities because diseased tissue is accessible through a simple blood draw. This enables longitudinal sampling that is impossible for solid tumors requiring invasive biopsies. Leukemias, lymphomas, myelomas, and myelodysplastic syndromes arise from hematopoietic stem and progenitor cells that circulate continuously through peripheral blood, with malignant cells often comprising 5–95% of white blood cell populations depending on stage and treatment.[1]

This accessibility supports serial biospecimen collection tracking disease evolution from diagnosis through treatment, remission, and potential relapse — a temporal resolution that reveals dynamic processes including clonal selection, resistance emergence, and minimal residual disease persistence.

Clonal evolution theory holds that cancers progress through sequential acquisition of genetic alterations conferring selective advantages, with successful subclones outcompeting predecessors.[2] In hematological malignancies this plays out over months to years. Serial Human Whole Blood and Human PBMCs collections capture these trajectories at high resolution.

Single-cell sequencing on longitudinal specimens reconstructs phylogenetic trees showing ancestor-descendant relationships between clones, identifies driver mutations, and reveals resistance mechanisms emerging during therapy.[3] These insights inform treatment strategy, suggest combinations that prevent resistance, and enable early relapse detection through minimal residual disease monitoring.

At Sanguine, our direct-to-donor model across the United States enables flexible serial collection wherever patients receive care — academic centers, community oncology practices, or home-based phlebotomy. Our longitudinal programs support monthly, quarterly, or event-driven collections spanning years, producing Human PBMCs, Human Plasma, Human Serum, Human Leukopak, and cell-type isolations including Human CD3+ T Cells and Human CD19+ B Cells from every timepoint. Detailed genomic annotation — treatment histories, response assessments, clinical outcomes — enables retrospective analyses from study design to receipt of samples.

Serial Sampling Strategies for Clonal Evolution Studies

Sampling frequency determines evolutionary resolution. Weekly collections reveal rapid clonal dynamics during intensive therapy, while quarterly sampling suffices for chronic diseases with slower progression.

Acute myeloid leukemia (AML) shows dramatic clonal shifts during induction chemotherapy, with founding clones declining rapidly while minor subclones expand within days to weeks.[4] Capturing this window requires weekly or bi-weekly Human Whole Blood collections during active treatment, though practical constraints often limit sampling to diagnosis, post-induction, and relapse. Chronic lymphocytic leukemia (CLL) progresses more gradually, with annual collections documenting evolution over decades before treatment and quarterly sampling during therapy.

Optimal Timepoint Selection for Hematological Studies:

• Diagnosis (pre-treatment baseline establishing founding clone genetics)
• During induction therapy (weekly or bi-weekly when feasible, capturing treatment-induced selection)
• Post-induction or post-consolidation (documenting treatment response and residual disease)
• Maintenance therapy (quarterly monitoring for emerging resistance or relapse)
• Relapse or progression (comparing evolved clones to diagnosis establishing resistance mechanisms)
• Post-transplant monitoring (monthly during first year when graft-versus-leukemia effects operate)
• Long-term follow-up (annual collections documenting clonal evolution in remission)
• Event-driven collections during complications, infections, or secondary malignancies

Event-driven collections supplement scheduled sampling, capturing biologically significant transitions — treatment changes, progression, remission, or complications. These priority collections are often more informative than scheduled timepoints, documenting selection pressures and clonal responses to specific interventions.[5] Unscheduled collections require rapid mobilization of collection teams and processing infrastructure, which Sanguine maintains through a nationwide mobile phlebotomy network enabling 48–72 hour turnaround from request to processed specimen.

Sample volume requirements vary by platform. Whole exome sequencing needs 1–5 μg genomic DNA, obtainable from 10 mL Human Whole Blood, while single-cell RNA sequencing typically analyzes 5,000–10,000 cells from 10–30 mL blood, depending on white cell counts.[6] Patients with high leukemic burden provide abundant material; patients in remission with minimal residual disease need larger volumes or enrichment to isolate rare malignant cells. Human Leukopak collections exceeding 100 mL support dozens of applications while banking reserves for future analyses.

Treatment-naive diagnostic specimens establish evolutionary starting points, documenting founding clone genetics before therapy reshapes the landscape. These “time zero” specimens enable retrospective identification of pre-existing resistance mutations present at low frequencies — undetectable by bulk sequencing but revealed through deep or single-cell methods.[7] Minor subclones harboring resistance mutations frequently expand under treatment, with trajectories often predictable from subclonal architecture at diagnosis. Banking adequate diagnostic material enables repeated interrogation as new resistance mechanisms or prognostic markers emerge.

Technological Approaches to Clonal Evolution Analysis

Bulk Sequencing Methods

Whole exome sequencing (WES) identifies protein-coding mutations distinguishing malignant clones from normal hematopoiesis by comparison with matched germline DNA from skin biopsies or CD3+ T cells. Standard WES detects mutations present in ≥5–10% of cells, capturing dominant clones and major subclones but potentially missing rare populations.[8] Its cost-effectiveness enables routine application to longitudinal collections, with variant allele frequencies quantifying clonal dynamics across timepoints — rising frequencies signal expansion, falling frequencies indicate response or immune elimination.

Targeted deep sequencing panels interrogating recurrently mutated genes achieve variant detection sensitivities of 0.1–1% through ultra-high coverage (10,000–50,000× per base).[9] Panels of 50–300 genes enable cost-effective monitoring of known mutations while discovering additional hotspot alterations. This targeted approach supports serial monitoring of many samples per patient with less specimen consumed — critical for banked collections where material is irreplaceable.

Minimal residual disease (MRD) monitoring via deep sequencing detects persistent malignant cells below morphological thresholds (<1% of nucleated cells). MRD positivity after induction strongly predicts relapse risk across multiple malignancies, with MRD-negative patients showing superior outcomes.[10] Personalized MRD assays designed for each patient’s founding mutations reach 1-in-100,000 sensitivity. Serial Human Whole Blood or Human PBMC collections at monthly intervals enable MRD kinetic analyses that can predict relapse months before clinical manifestation.

Single-Cell Approaches

Single-cell DNA sequencing reconstructs tumor phylogenies at high resolution, assigning individual cells to clonal lineages based on shared mutations and inferring the order of mutation acquisition.[11] It reveals branching evolutionary patterns where multiple subclones coexist, quantifies subclonal diversity, and identifies rare resistant populations. Applied serially, it tracks clonal expansions and contractions, documents extinction events under treatment, and reveals parallel evolution where independent clones acquire similar resistance mutations.

Single-cell RNA sequencing (scRNA-seq) complements genomic analysis by profiling transcriptional states — proliferation rates, differentiation states, and pathway activation. The same mutation can produce different phenotypes depending on cellular context, and scRNA-seq distinguishes functionally distinct states within genetically homogeneous clones.[12] Applied to serial Human PBMCs, it tracks both genetic evolution and phenotypic transitions, revealing treatment-induced differentiation or quiescence preceding genetic resistance.

Multi-omic single-cell approaches simultaneously profile DNA mutations, RNA expression, and surface proteins from individual cells, integrating information impossible to obtain separately.[13] This correlates specific mutations with cellular phenotypes — for example, RAS-pathway-activating mutations produce characteristic transcriptional signatures detectable before morphological transformation. Our Human Leukopak products provide the cell quantities (50,000–100,000 cells per sample per timepoint) that comprehensive single-cell multi-omics requires.

Disease-Specific Evolutionary Patterns

Acute Myeloid Leukemia

AML shows rapid clonal dynamics, with founder clones dominant at diagnosis then shifting dramatically during therapy. Induction chemotherapy creates intense selective pressure favoring resistant subclones, with common mechanisms including TP53 mutations, RAS pathway activation, and chromatin-remodeling fusions.[14] Serial sampling every 1–2 weeks during induction reveals these shifts in real time, with Human Whole Blood sufficient for repeated genomic profiling. Post-remission collections identify residual populations that can regenerate relapse months later, detectable at frequencies below 0.1%.

AML Serial Sampling Protocol:

• Pre-treatment diagnosis (30–50 mL blood for comprehensive multi-platform analysis)
• Day 14 post-induction (bone marrow aspiration + 10 mL blood)
• Day 28 post-induction response assessment (20 mL blood)
• Pre-consolidation (10 mL blood)
• Post-consolidation cycles (10 mL blood each)
• Monthly MRD monitoring during remission (10 mL blood)
• At relapse if occurs (30 mL blood comparing to diagnosis)
• Allogeneic transplant recipients: weekly first month, monthly ongoing

Chronic Lymphocytic Leukemia

CLL typically progresses indolently over years to decades before treatment, with quarterly or annual collections documenting gradual clonal evolution and acquisition of high-risk alterations including TP53 mutations, NOTCH1 mutations, or complex karyotypes. But CLL shows punctuated equilibrium — long stability interrupted suddenly by rapid clonal expansion.[15] These transitions often coincide with Richter transformation to aggressive lymphoma or treatment-refractory disease. Our Human PBMCs from untreated CLL patients show median purities exceeding 70% lymphocytes, with malignant B cells identifiable by CD5+CD19+ immunophenotyping.

CLL Longitudinal Collection Strategy:

• Diagnosis (30 mL for banking given years before treatment likely)
• Annually during watch-and-wait (10 mL each, tracking clonal evolution)
• Upon treatment initiation (20 mL pre-treatment)
• Quarterly during active therapy (10 mL monitoring response)
• Annually during long-term follow-up post-therapy
• Immediately if Richter transformation suspected (30 mL)

Myelodysplastic Syndromes

MDS are clonal hematopoietic disorders marked by ineffective hematopoiesis, cytopenias, and variable progression to AML. Clonal architecture at diagnosis predicts transformation risk — patients with multiple clones show higher AML progression rates than those with a dominant single clone.[16] Serial Human Whole Blood and Human Leukopak collections every 3–6 months document clonal evolution, identifying expanding high-risk clones months before morphological AML transformation. TP53-mutant clones particularly associate with resistance and poor outcomes, and serial deep sequencing detects early expansions enabling preemptive intervention.

Multiple Myeloma

Myeloma clonal evolution occurs in bone marrow plasma cells rather than peripheral blood, complicating longitudinal sampling since bone marrow aspirations are more invasive than blood draws. However, circulating plasma cells enter peripheral blood in advanced disease, enabling Human Whole Blood monitoring when flow cytometry confirms adequate circulating numbers.[17] Cell-free DNA shed from bone marrow plasma cells circulates in Human Plasma, enabling liquid biopsy tracking of myeloma-specific mutations without repeated bone marrow procedures. Serum M-protein quantification from Human Serum provides a standard disease-activity measure.

Immune Microenvironment Dynamics

Hematological malignancies evolve within complex immune microenvironments where malignant cells evade surveillance while normal immune populations attempt elimination. T cells targeting tumor-associated antigens exert selective pressure favoring immune evasion — antigen loss, MHC downregulation, and immunosuppressive cytokine production.[18] Serial flow cytometric immunophenotyping of Human PBMCs documents immune dynamics paralleling clonal evolution, revealing exhausted T cell phenotypes (PD-1, TIM-3, LAG-3) accumulating during progression.

Key Immune Populations to Track Longitudinally:

• Regulatory T cells (CD4+CD25+FOXP3+) suppressing antitumor immunity
• Exhausted CD8+ T cells (PD-1+TIM-3+) with impaired cytotoxic function
• Activated NK cells (CD56+CD16+) mediating tumor surveillance
• Myeloid-derived suppressor cells (MDSCs) inhibiting immune responses
• Tumor-infiltrating lymphocytes (when bone marrow available)
• Plasma cytokines including IL-6, IL-10, TGF-β shaping immune environments

Immunotherapy produces dramatic clonal shifts as treatments activate immune attack on malignant clones. Checkpoint inhibitors blocking PD-1 or CTLA-4 reverse T cell exhaustion, enabling reinvigorated surveillance that eliminates previously dominant clones.[19] CD19 CAR T cell therapies eliminate B cell malignancies but select for CD19-negative escape variants — resistance detectable by serial flow cytometry on Human PBMCs months before clinical relapse. Serial immune profiling paired with clonal evolution tracking reveals whether resistance arises through genetic evolution or immune escape, informing whether subsequent treatments should target different antigens or activation strategies.

Practical Considerations for Serial Collection Programs

Patient compliance determines longitudinal study success, and collection burden directly affects retention. Minimizing travel through home-based phlebotomy, coordinating research draws with clinical visits, and clearly communicating research value all improve adherence.[20] Financial compensation for time and discomfort acknowledges contributions while remaining ethically appropriate. Sanguine’s nationwide mobile phlebotomy network enables collections wherever patients prefer — home, workplace, or clinic.

Strategies Maximizing Longitudinal Study Retention:

• Flexible scheduling accommodating patient availability
• Mobile phlebotomy eliminating travel requirements
• Coordination with clinical blood draws minimizing needle sticks
• Regular communication maintaining engagement between collections
• Results sharing when appropriate and IRB-approved
• Annual newsletters describing study progress and scientific impact
• Appropriate compensation respecting participant time
• Streamlined consent allowing remote enrollment
• Text or email appointment reminders
• Backup collection windows if patients miss scheduled appointments
• Clear communication of study duration and expected visits
• Participant advisory boards providing input into protocol design

Processing standardization is critical when comparing samples collected months apart at different sites or by different personnel. Standard operating procedures specifying tubes, processing timing, centrifugation parameters, and cryopreservation minimize technical variability that could be misread as biological evolution.[21] Processing time from phlebotomy to cryopreservation particularly affects cell viability and gene expression, with delays inducing stress responses that alter phenotypes. Sanguine’s processing laboratories across the United States enable <24 hour collection-to-processing timelines even for remote patients.

Inventory management for longitudinal studies requires tracking dozens to hundreds of aliquots per patient across timepoints, with database systems linking specimens to clinical data. Many studies span 5–10 years, with specimen access occurring years after banking.[22] Detailed annotation — collection dates, processing methods, storage locations, freeze-thaw history, remaining volumes — lets researchers select optimal specimens while preserving irreplaceable material.

Analytical Workflows Integrating Multi-Timepoint Data

Phylogenetic Tree Reconstruction

Computational methods reconstruct clonal phylogenies from multi-sample sequencing data, inferring ancestor-descendant relationships and mutation-acquisition order. These phylogenies reveal whether evolution proceeds linearly, with sequential clonal replacement, or through branching, with multiple coexisting lineages.[23] Trunk mutations present in all samples represent early events potentially targetable to eliminate all descendant clones, while branch mutations arising later are less attractive targets since hitting single branches leaves others intact.

Tools including CITUP, PyClone, and PhyloWGS infer clonal architectures from bulk sequencing variant allele frequencies, while single-cell methods including SCITE and OncoNEM work directly from single-cell genotype data.[24] These algorithms account for sequencing errors, normal cell contamination, and copy number alterations. Integrating multi-timepoint data improves phylogeny inference over single-sample analyses, with temporal constraints excluding implausible trajectories.

Longitudinal Trajectory Analysis

Time-course analyses identify genes whose mutations consistently expand or contract across cohorts, revealing recurrent drivers of progression or resistance. Mixed-effects models account for patient-to-patient variability while identifying consistent trends, separating random drift from selection-driven dynamics.[25] These population-level analyses complement single-patient phylogenies, identifying generalizable evolutionary principles.

Predictive modeling with machine learning trained on early-timepoint data forecasts likely trajectories and relapse probability. These models integrate baseline clonal architecture, mutation profiles, treatment regimens, and clinical covariates.[26] Prospective validation against observed later-timepoint evolution assesses accuracy, with successful models potentially enabling personalized treatment selection before resistance emerges.

Check Our Inventory

Ready to launch your longitudinal hematological disease research?

Sanguine’s comprehensive specimen menu supports serial collections from diagnosis through treatment and long-term follow-up. Our Human PBMCs, Human Plasma, Human Leukopak, and specialized isolations enable multi-platform clonal evolution studies from study design to receipt of samples.

Request a Custom Quote →

Ethical Sourcing and Regulatory Compliance

All Sanguine biospecimens are collected under IRB-approved protocols with comprehensive informed consent. Our HIPAA-compliant systems protect privacy while enabling detailed genomic annotation. We maintain ISO 9001:2015 and ISO 13485:2016 certifications demonstrating quality management across operations. Donor compensation follows ethical guidelines, and geographic diversity in our network across the United States advances health equity. Specimens are designated Research Use Only (RUO) with clear documentation.

References

1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136-1152. doi:10.1056/NEJMra1406184
2. Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481(7381):306-313. doi:10.1038/nature10762
3. Morita K, Wang F, Jahn K, et al. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020;11(1):5327. doi:10.1038/s41467-020-19119-8
4. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481(7382):506-510. doi:10.1038/nature10738
5. Rampal R, Ahn J, Abdel-Wahab O, et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci USA. 2014;111(50):E5401-E5410. doi:10.1073/pnas.1407792111
6. Paguirigan AL, Smith J, Meshinchi S, et al. Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia. Sci Transl Med. 2015;7(281):281re2. doi:10.1126/scitranslmed.aaa0763
7. Shlush LI, Mitchell A, Heisler L, et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature. 2017;547(7661):104-108. doi:10.1038/nature22993
8. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-2074. doi:10.1056/NEJMoa1301689
9. Kennedy SR, Schmitt MW, Fox EJ, et al. Detecting ultralow-frequency mutations by duplex sequencing. Nat Protoc. 2014;9(11):2586-2606. doi:10.1038/nprot.2014.170
10. Short NJ, Kantarjian H, Ravandi F, Daver N. Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. Ther Adv Hematol. 2019;10:2040620719827310. doi:10.1177/2040620719827310
11. Kim C, Gao R, Sei E, et al. Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell. 2018;173(4):879-893.e13. doi:10.1016/j.cell.2018.03.041
12. van Galen P, Hovestadt V, Wadsworth Ii MH, et al. Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity. Cell. 2019;176(6):1265-1281.e24. doi:10.1016/j.cell.2019.01.031
13. Rattray NJW, Hamrang Z, Trivedi DK, et al. Metabolic dysregulation in vitamin E and carnitine shuttle energy mechanisms associate with human frailty. Nat Commun. 2019;10(1):5027. doi:10.1038/s41467-019-12716-2
14. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150(2):264-278. doi:10.1016/j.cell.2012.06.023
15. Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526(7574):525-530. doi:10.1038/nature15395
16. Makishima H, Yoshizato T, Yoshida K, et al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet. 2017;49(2):204-212. doi:10.1038/ng.3742
17. Lohr JG, Kim S, Gould J, et al. Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. Sci Transl Med. 2016;8(363):363ra147. doi:10.1126/scitranslmed.aac7037
18. Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2015;21(4):687-692. doi:10.1158/1078-0432.CCR-14-1860
19. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-1355. doi:10.1126/science.aar4060
20. Treweek S, Pitkethly M, Cook J, et al. Strategies to improve recruitment to randomised trials. Cochrane Database Syst Rev. 2018;2(2):MR000013. doi:10.1002/14651858.MR000013.pub6
21. Betsou F, Gunter E, Clements J, et al. Identification of evidence-based biospecimen quality-control tools. Biopreserv Biobank. 2013;11(2):110-118. doi:10.1089/bio.2012.0053
22. Henderson GE, Cadigan RJ, Edwards TP, et al. Characterizing biobank organizations in the U.S. J Biorepository Sci Appl Med. 2013;2013(1):3-12. doi:10.2147/BSAM.S37942
23. Kuipers J, Jahn K, Raphael BJ, Beerenwinkel N. Single-cell sequencing data reveal widespread recurrence and loss of mutational hits in the life histories of tumors. Genome Res. 2017;27(11):1885-1894. doi:10.1101/gr.220707.117
24. Jahn K, Kuipers J, Beerenwinkel N. Tree inference for single-cell data. Genome Biol. 2016;17:86. doi:10.1186/s13059-016-0936-x
25. Williams MJ, Werner B, Barnes CP, et al. Identification of neutral tumor evolution across cancer types. Nat Genet. 2016;48(3):238-244. doi:10.1038/ng.3489
26. Acar A, Nichol D, Fernandez-Mateos J, et al. Exploiting evolutionary steering to induce collateral drug sensitivity in cancer. Nat Commun. 2020;11(1):1923. doi:10.1038/s41467-020-15596-z